Evidence map›Paper›PMID 21819572›Full record

ArticleBMC microbiology2011

A galU mutant of Francisella tularensis is attenuated for virulence in a murine pulmonary model of tularemia.

Himangi R Jayakar, Jyothi Parvathareddy, Elizabeth A Fitzpatrick, Xiaowen R Bina, James E Bina, Fabio Re, Felicia D Emery, Mark A Miller

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Anti-virulence and bactericidal activities of Stattic againstApplied and environmental microbiology · 2023
    Article
  4. Contribution ofFrontiers in cellular and infection microbiology · 2023
    Article
  5. Deletion Mutants ofPathogens (Basel, Switzerland) · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Evasion of inflammasome activation by microbial pathogens.The Journal of clinical investigation · 2015
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Himangi R JayakarDepartment of Microbiology, Immunology, and Biochemistry, The University of Tennessee Health Science Center, Memphis, 38163, USA.
Jyothi Parvathareddy
Elizabeth A Fitzpatrick
Xiaowen R Bina
James E Bina
Fabio Re
Felicia D Emery
Mark A Miller
University of Tennessee Health Science Center · USScripps Research Institute · US

Funding

Yessinia autotransporters (Yaps): Structure, function, and host responseU54AI057157 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FRELINGER, JEFFREY ALLEN · 2003 to 2013
$91.4M
VSV as a vector for cytokine-assisted tularemia vaccinesU01AI061260 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MILLER, MARK A · 2005 to 2009
$2.9M
Identification of Francisella tularensis extracellular proteins expressed in vivoR21AI079482 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI BINA, JAMES EDWARD · 2009 to 2010
$407k
NIAID NIH HHS AI061260NIAID NIH HHS AI079482NIAID NIH HHS R21 AI079482NIAID NIH HHS U54 AI057157
6 · The paper itself

Abstract

backgroundA number of studies have revealed that Francisella tularensis (FT) suppresses innate immune responses such as chemokine/cytokine production and neutrophil recruitment in the lungs following pulmonary infection via an unidentified mechanism. The ability of FT to evade early innate immune responses could be a very important virulence mechanism for this highly infectious bacterial pathogen.

resultsHere we describe the characterization of a galU mutant strain of FT live vaccine strain (LVS). We show that the galU mutant was highly attenuated in a murine model of tularemia and elicited more robust innate immune responses than the wild-type (WT) strain. These studies document that the kinetics of chemokine expression and neutrophil recruitment into the lungs of mice challenged with the galU mutant strain are significantly more rapid than observed with WT FT, despite the fact that there were no observed differences in TLR2 or TLR4 signaling or replication/dissemination kinetics during the early stages of infection. We also show that the galU mutant had a hypercytotoxic phenotype and more rapidly induced the production of IL-1β following infection either in vitro or in vivo, indicating that attenuation of the galU mutant strain may be due (in part) to more rapid activation of the inflammasome and/or earlier death of FT infected cells. Furthermore, we show that infection of mice with the galU mutant strain elicits protective immunity to subsequent challenge with WT FT.

conclusionsDisruption of the galU gene of FTLVS has little (if any) effect on in vivo infectivity, replication, or dissemination characteristics, but is highly attenuating for virulence. The attenuated phenotype of this mutant strain of FT appears to be related to its increased ability to induce innate inflammatory responsiveness, resulting in more rapid recruitment of neutrophils to the lungs following pneumonic infection, and/or to its ability to kill infected cells in an accelerated fashion. These results have identified two potentially important virulence mechanisms used by FT. These findings could also have implications for design of a live attenuated vaccine strain of FT because sublethal infection of mice with the galU mutant strain of FTLVS promoted development of protective immunity to WT FTLVS.

Indexed as

AnimalsChemokinesDisease Models, AnimalFrancisella tularensisHumansInterleukin-1betaLungMiceMice, Inbred C57BLNeutrophilsPneumonia, BacterialRodent DiseasesToll-Like Receptor 2Toll-Like Receptor 4TularemiaUTP-Glucose-1-Phosphate UridylyltransferaseChemokinesInterleukin-1betaTlr2 protein, mouseTlr4 protein, mouseToll-Like Receptor 2Toll-Like Receptor 4UTP-Glucose-1-Phosphate UridylyltransferaseVirulence Factors

Identifiers

PMID21819572
PMCPMC3173336
OpenAlexW2134610166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.